ASH 2023 | Real-world outcomes of teclistamab for R/R multiple myeloma
Hamza Hashmi, MD, Medical University of South Carolina, Charleston, SC, presents real-world data on the safety and efficacy of teclistamab for patients with heavily pretreated relapsed/refractory (R/R) multiple myeloma (MM). With a median follow-up of 3.5 months, the best overall response rate (ORR) was 65%, although a low progression-free survival (PFS) indicates that remission was not durable. Adverse events (AEs) of cytokine release syndrome (CRS) were generally well-managed with tocilizumab, while neurotoxicity was treated with dexamethasone. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
